Introduction
============

Contrast-induced nephropathy (CIN) is a commonly observed undesirable condition in patients undergoing percutaneous coronary intervention (PCI). CIN is related with poorer outcomes for patients, including need for renal dialysis and higher mortality^[@r1]-[@r3]^. Previous studies reported that the prevalence of CIN after CAG or PCI procedures range from 2%-15% and can reach up to 50% in patients under high risk such as diabetes mellitus (DM) and pre-procedural renal failure^[@r4],[@r5]^. CIN was previously defined as an increase in baseline serum creatinine level (Cr) 25% or 0.5 mg/ dL within 48-72 h after PCI^[@r1]-[@r3]^. Although, the physiological mechanisms of CIN are not certain, oxidative stress, inflammation, renal medullary hypoxia, and negative effects of contrast media are supposed to be the underlying physiological mechanisms^[@r6]-[@r9]^. The previous studies determined that age, DM, heart failure, anemia, chronic (preexisting) kidney disease, hypoalbuminemia, metabolic syndrome, overuse of high osmolar contrast medium, and peripheral vascular disease are predictors of CIN^[@r1]-[@r9]^. Also, relation between body mass index (BMI) and development of CIN were evaluated in different studies and the results are confounding^[@r1]-[@r4]^. The clinical impact of malnutrition has been shown in chronic kidney disease and cardiovascular diseases^[@r5]-[@r8]^. Geriatric nutritional risk index (GNRI) is a simple tool to identify the nutritional status of subjects. The clinical impact of GNRI has been demonstrated in many diseases^[@r9]-[@r12]^. GNRI is calculated using a simple formula that contains albumin and BMI.

According to past medical knowledge and consensus, the impact of GNRI in development of CIN after PCI in non-ST-segment elevation myocardial infarction (NSTEMI) patients has not been evaluated yet. The aim of present study is evaluation of whether GNRI could predict CIN after PCI in NSTEMI patients.

Material and Methods
====================

All patients diagnosed with non-STEMI who had undergone PCI in our center between January 1, 2018 and December 31, 2018 were retrospectively enrolled in the present study. Patients that were followed-up with medical therapy, those with a history of heart failure, active malignancy, hematologic disorder, kidney transplantation or end-stage renal disease requiring dialysis, nephrotic syndrome, liver dysfunction, systemic immune system, or connective tissue disease or given contrast media within the last two weeks, were excluded from the study. Also, patients who had used the nephrotoxic drugs during periprocedural period, and had not measured their serum creatinine levels before and 72 hours after the procedure were excluded from the study. Patients with typical chest pain, objective signs of myocardial ischemia, and elevated biochemical markers of myocardial necrosis were diagnosed with NSTEMI^[@r13]^. All patients included in the study received same low-osmolar contrast material.

Hypertension was defined as systolic and diastolic blood pressures ≥140/90 mmHg or use of any antihypertensive drug. Diabettes mellitus (DM) was defined as fasting blood glucose ≥126 mg/ dL or HbA1c ≥6.5 or use of any antidiabetic drug. Dyslipidemia was determined as total cholesterol level \>200 mg/dL, and/or undergoing treatment with statins and/or lipid-lowering agents. Current smoker was defined as the patient smoking at least 1 cigarette/day for at least one year.

The baseline characteristics of patients were recorded from patients' files, and routine laboratory parameters were retrieved from the hospital laboratory digital system. Transthoracic echocardiography was performed by experienced echocardiographers according to relevant guidelines^[@r14]^. GNRI values were calculated from the hospital admission database. The GNRI was calculated using a previously reported formula: GNRI = 14.89 × albumin (g/dL) + 41.7 × body weight (kg)/ideal body weight (kg). The ideal body weight was calculated as follows: body height - 100 - \[(body height -150)/4\] for males, and body height - 100 - \[(body height - 150)/2.5\] for females. The patients were classificated into CIN (+) and CIN (-) groups. The local ethics committee approved the protocol of the study.

Statistical analyses
--------------------

Continuous variables with normal distribution were summarized as mean (±standart deviation) and compared between groups with Student's t-test. Variables without normal distribution summarized as median and interquartile range and compared between groups with Mann-Whitney U-test. Categorical variables were summarized as numbers and percentages and compared using chi-square test. To demonstrate the sensitivity and specificity of GNRI, albumin, and BMI and their cut-off values for CIN development, the receiver operating characteristics (ROC) curve was used. The area under curve (AUC) comparison of GNRI, albumin, and BMI were performed using the Delong method^[@r15]^. To predict independent parameter for CIN development multivariate logistic regression analysis were performed.

Two programs were used for statistical analysis: Statistical Package for the Social Sciences (SPSS 20.0) (SPSS Inc., Chicago, Illinois, USA) and Med-Calc 15 statistical software (Ostend, Belgium). Statistical significance was considered when p value was \<0.05%.

Results
=======

During the study period, 1116 patients (33.4% female, mean age 60.61±10.73 years) were included in the study. Of those, 190 (17.0%) developed CIN. Baseline demographic and medical characteristics of groups are presented in [Table 1](#T1){ref-type="table"}. Compared to the CIN (-) group, the mean age of the CIN (+) group was statistically significantly higher (64.8±10.7 vs. 60.5±10.6; p\<0.001). The mean values of height, body weight, and BMI were significanlty lower in CIN (+) group than CIN (-) group (p\<0.001, for all). Compared to the CIN (-) group, the rates of smoking and chronic obstructive pulmonary disease were significantly lower in the CIN (+) group (p\<0.05, for both). Left ventricular ejection fraction (LVEF) was significantly higher in the CIN (-) group than CIN (+) group (54.3%±7.2% vs. 50.7%±9.1%; p\<0.001). Laboratory parameters of groups are summarized in [Table 2](#T2){ref-type="table"}. Serum albumin level was significantly lower in the CIN (+) group (3.71±0.52 g/dL vs. 3.94±0.53 g/dL; p\<0.001). Pre-procedural serum creatinine levels were similar between groups (CIN (+) 0.84±0.33 mg/dL vs. CIN (-) 0.88±0.34 mg/dL; p\<0.160), as expectedly post-procedural creatinine levels were statistically higher in the CIN (+) group (1.24±0.58 mg/dL vs. 0.91±0.33 mg/dL; p\<0.001). Also, mean serum uric acid level, and white blood cell (WBC) count were significantly higher and hemoglobin level was lower in the CIN (+) group than the CIN (-) group ([Table 2](#T2){ref-type="table"}). The mean GNRI was significantly lower in the CIN (+) group than the CIN (-) group (101.4±8.7 vs. 112.1±12.9; p\<0.001) ([Table 1](#T1){ref-type="table"}).

###### 

Baseline demographic and clinical characteristics and echocardiographic parameters of patients.

  Parameters                                     All Patients N=1116   CIN (+) N=190   CIN (--) N=926   P
  ---------------------------------------------- --------------------- --------------- ---------------- -----------
  Age, year                                      60.61±10.73           64.8±10.67      60.5±10.6        \<0.001\*
  Weight, kg                                     77.4±13.4             66.6±5.2        79.6±13.5        \<0.001\*
  Height, m                                      1.67±0.08             1.65±0.08       1.67±0.07        \<0.001\*
  BMI, kg/m^[@r2]^                               27.3±4.6              26.6±4.1        28.43±4.59       \<0.001\*
  Female, % (n)                                  33.8 (377)            34.7 (66)       33.6 (311)       0.760
  Obesity, % (n)                                 30.2 (337)            19.5 (37)       32.4 (300)       \<0.001\*
  Diabetes mellitus, % (n)                       38.1 (425)            44.7 (85)       36.7 (340)       0.038\*
  Hypertension, % (n)                            69.4 (775)            68.9 (131)      69.5 (644)       0.870
  Hyperlipidemia, % (n)                          39.0 (435)            36.3 (69)       39.5 (366)       0.409
  Heart failure, % (n)                           15.4 (171)            17.4 (33)       14.9 (138)       0.397
  Chronic obstructive pulmonary disease, % (n)   12.2 (136)            7.9 (15)        13.1 (121)       0.047
  Smoker, % (n)                                  40.1 (447)            33.2 (63)       41.5 (384)       0.033\*
  Stroke, % (n)                                  3.4 (38)              4.2 (8)         3.2 (30)         0.505
  GNRI                                           110.3±12.9            101.4±8.7       112.1±12.9       \<0.001\*
  Contrast volume (mL)                           182.6±58.6            177±49.5        183±60           0.183
  **Echocardiography Parameters**                                                                       
  LVESV, mL                                      55.2±15.1             60.5±18.42      54.1±13.99       \<0.001\*
  LVEDV, mL                                      118±19.5              121.5±20.68     118.0±19.29      0.027\*
  LVEF, %                                        53.7±7.67             50.7±9.07       54.3±7.20        \<0.001\*
  sPAP, mmHg                                     22.7±5.65             23.6±4.89       22.6±5.79        0.898

BMI: body mass index, CIN: contrast induced nephropathy, GNRI: geriatric nutritional index, LVEDV: left ventricular end-diastolic volume, LVEF: left vetricular ejection fraction, LVESV: left vetricular end-systolic volume, sPAP: systolic pulmonary artery pressure. \*Statistically significant

###### 

Comparision of blood parameters of patients.

  Parameters                            All Patients N=1116   CIN (+) N=190   CIN (--) N=926   P
  ------------------------------------- --------------------- --------------- ---------------- -----------
  Total Protein, (g/dL)                 6.64±0.83             6.59±0.62       6.65±0.87        0.356
  Albumin, (g/dL)                       3.9±0.5               3.71±0.52       3.94±0.53        \<0.001\*
  Pre-Procedural Creatinine, (mg/dL)    0.87±0.34             0.84±0.33       0.88±0.34        0.160
  Post-Procedural Creatinine, (mg/dL)   0.97±0.40             1.24±0.58       0.91±0.33        \<0.001\*
  Uric acid, (mg/dL)                    5.54±1.52             5.91±2.04       5.47±1.36        0.005\*
  Total bilirubin, (mg/dL)              0.55±0.31             0.51±0.27       0.56±0.32        0.046\*
  WBC, (109/L)                          9100±2890             9572±3347       9016±2781        0.033\*
  Haemoglobin, (g/dL)                   13.8±5.37             13.0±2.20       14.0±5.80        0.022\*
  Haematocrit, %                        40.2±5.1              38.7±5.9        40.5±4.89        \<0.001\*
  Platelet, (109/L)                     244±73                235±83          246±71           0.117
  Lymphocyte, (109/L)                   2160±960              2159±1036       2162±951         0.971
  Neutrophil, (109/L)                   5930±2432             6359±2934       5841±2308        0.023\*
  Monocyte, (109/L)                     1020±650              1053±484        1012±686         0.333
  Total cholesterol (mg/dL)             186±43                179±38          188±44           0.004\*
  LDL-C (mg/dL)                         121±34                119±32          122±35           0.226
  HDL-C (mg/dL)                         40±11                 38±10           40±11            0.011\*
  Triglyceride (mg/dL)                  163±99                147±77          166±103          0.005\*
  Glucose, (mg/dL)                      148±75                169±85          144±72           \<0.001\*
  HbA1c, %                              6.6±1.8               6.77±1.62       6.61±1.79        0.262
  Troponin I, (ng/L)                    66 (18-456)           166 (30-1792)   58 (18-368)      \<0.001\*
  BNP, (ng/L)                           246 (98-1210)         260 (87-1600)   274 (94-1053)    0.341

BNP: brain natriuretic peptide, CIN: contrast induced nephropathy, HDL-C: high density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol.

\* Statistically significant

###### 

Logistic regression analysis for predictors of contrast-induced nephropathy.

  Analysis                              Univariate   Multivariate                      
  ------------------------------------- ------------ --------------------- ----------- ---------------------
  Age (per 1 year increase)             \<0.001\*    1.036 (1.020-1.052)   \-          \-
  Diabetes mellitus (yes vs. no)        0.039\*      1.395 (1.018-1.913)   \-          \-
  Weight (per 1 kg decrease)            \<0.001\*    0.867 (0.845-0.890)   \-          \-
  BMI (per 1 kg/m**2** decrease)        \<0.001\*    0.905 (0.870-0.943)   0.004\*     0.942 (0.905-0.981)
  Albumin (per 1 g/dL decrease)         \<0.001\*    0.468 (0.355-0.619)   0.019\*     0.979 (0.962-0.996)
  GNRI (per 1 point decrease)           \<0.001\*    0.871 (0.848-0.895)   \<0.001\*   0.762 (0.725-0.801
  LVEF (per 1% decrease)                \<0.001\*    0.949 (0.932-0.966)   0.009\*     0.971 (0.951-0.993)
  Uric acid (per 1 mg/dL increase)      \<0.001\*    1.177 (1.080-1.310)   \-          \-
  Hemoglobin (per 1 g/dL decrease)      \<0.001\*    0.847 (0.782-0.918)   \-          \-
  HDL-C (per 1 mg/dL decrease)          0.011\*      0.981 (0.966-0.996)   \-          \-
  Triglyceride (per 1 mg/dL decrease)   0.020\*      0.998 (0.996-1.000)   \-          \-
  Troponin (per 1 ng/dL increase)       \<0.001\*    1.001 (1.000-1.001)   \-          \-

BMI: body mass index, HDL-C: high denstiy, GNRI: geriatric nutritional index, LVEF: left vetricular ejection fraction

\*Statistically significant

To predict CIN development, the cut-off value of albumin ≤3.8 g/dL has a 60.0% sensitivity and 65.66% specificity (AUC: 0.637; 95% confidence interval \[CI\] 0.608-0.665; p\<0.001) and BMI ≤27 kg/m^[@r2]^ has a 66.32% sensitivity and 51.51% specificity (AUC: 0.615; 95% CI 0.586-0.644; p\<0.001), and GNRI ≤110.7 has a 85.8% sensitivity and 55.2% specificity (AUC: 0.757; 95% CI 0.7310.782; p\<0.001) in the ROC curve analyses ([Figure 1](#F1){ref-type="fig"}). In the pairwise comparison of ROC analyses, GNRI was found to be a statistically significant better than albumin and BMI in predicting development of CIN (for both; p\<0.001) ([Figure 1](#F1){ref-type="fig"}).

![Comparison of Receiver operating characteristic (ROC) curves for CIN development.](MEDJ-35-047-f1){#F1}

To define the predictors of CIN, univariate and multivariate logistic regression analyses were performed and results are summarized in Table 4. The univariate analysis demonstrated that history of DM, age, BMI, weight, LVEF, GNRI, and levels of troponin, uric acid, HDL-C, triglyceride, hemoglobin and albumin were predictors of CIN development. The multivariate analysis that examined age, BMI, weight, DM, LVEF, GNRI, and troponin, uric acid, HDL-C, triglyceride, hemoglobin and albumin levels demostrated that albumin (per 1- g/dL decrease) (OR: 0.979; 95% CI 0.9620.996; p=0.019), BMI (per 1 kg/m^[@r2]^ decrease) (OR: 0.942; 95% CI: 0.905-0.981; p=0.004), GNRI (per 1 point decrease) (OR: 0.762; 95% CI 0.7250.801; p\<0.001), and LVEF (per 1% decrease) (OR: 0.971; 95% CI 0.951-0.993; p=0.009) were the independent predictors of CIN development.

Discussion
==========

In our study, we showed that low values of GNRI, serum albumin, BMI, and LVEF were independent predictors of CIN. Moreover, GNRI was better than both serum albumin and BMI in predicting development of CIN after PCI.

CIN is a frequent cause of acute kidney disease in hospitalized patients. Published studies have reported an increase rate of CIN in patients diagnosed with acute coronary syndrome and had undergone PCI. The prevalance of CIN in patients diagnosed with myocardial infarction and underwent PCI was found to be between 12 and 26%^[@r16][@r18]^. Since there is no sole marker for CIN, many markers have been reported to be related with CIN development^[@r16]-[@r19]^. Previous medical history of diabetes mellitus (DM) or chronic kidney diseases have been shown to be significant risk factors of CIN development after PCI^[@r16]-[@r19]^. Also, the contrast agent volume is an important risk factor for CIN development. Moreover, many other risk factors that are related to CIN development have been reported in different studies that performed PCI including advanced age, previous history of heart failure, hypoalbuminemia, anemia, C-reactive protein, low BMI, nephrotoxic drugs use, hemodynamic instability, white blood cell count and use of intra-aortic ballon pump^[@r16]-[@r18],[@r20]-[@r22]^. The pathophysiology of CIN is not clear. The inflammation, oxidative stess, renal medullar hypoxia, negative effects of contrast agents, impaired balance of vasodilation and vasoconstriction in renal medulla have been considered to be possible risk factors for the developmet of CIN. The association between hypoalbuminemia and cardiovascular morbidity/mortality has been shown in different studies. Moreover, studies have demonstrated that low serum albumin level is related to mortality in patients diagnosed with acute coronary syndrome^[@r17],[@r23]-[@r25]^. However, the relationship between serum albumin and CIN is not clear, and several possible mechanisms may be involved. Antioxidative effects of albumin are important for the development of CIN. Because albumin is an important free oxygen radical capture from plasma and oxidative stress is a possible factor to the development of CIN, the low level of albumin is an significant predictor of CIN development^[@r26],[@r27]^. Another possible relationship between albumin and CIN may be explained by inceased inflammation status in CIN patients^[@r28],[@r29]^. Due to an inverse relation between inflamation and albumin, low albumin levels in CIN patients might be explained by increased inflamation status. The relation between BMI and CIN development has been evaluated in different studies and the results are confounding^[@r1]-[@r4]^. Some studies have shown that low BMI, while others have established that a high BMI is a risk factor. Recently, Kuno et al.^[@r2]^ showed that the relationship between BMI and CIN is a reverse J-curve relationship and the incidence of CIN is high both in patients with BMIs \<20 kg/m^[@r2]^ and \>30 kg/m^[@r2]^ than those with BMIs between 20-30 kg/m^[@r2]^. In the present study, we have shown that mean BMI of the CIN (+) group is lower than the CIN (-) group and BMI is an independent predictor of CIN development. GNRI is a simple index and well-established nutritional screening tool for elderly patients that has been evaluated in various cardiovascular diseases^[@r9]-[@r12],[@r30]^. Malnutrition is common in patients suffered from a cardiovascular disease especially in heart failure patients^[@r10],[@r30]^. The valid formula for the GNRI include serum albumin levels and weights of patients. Also, the formula included ideal weight of patients which is calculated from body height. In this present study, we showed that the GNRI is an independent predictor of CIN development. Moreover, it is significantly better than both serum albumin levels and BMI in predicting CIN development. The possible assocation between CIN development and malnutrition is not certain. The most possible symptom is inflammation. As emphasized above, inflammation is related to CIN development and malnutrition is closely associated with systemic inflammation. Consequently, patients with malnutrition are likely to experience CIN. Moreover, similar to BMI, GNRI is affected by both body weight and height. However, in the formula of GNRI the ideal body weight is also calculated which might explain the difference between BMI and GNRI. Many previous studies reported that CIN development is frequently seen in advanced age patients^[@r31]-[@r33]^. The possible mechanisms underlying CIN development in the elderly age is not clear but probably is associated with change in renal function with aging. In the present study, we found in the multivariate analysis, that age is not an independent predictor of CIN development. This might explain the reason why the mean age of study population was 60.61±10.73 years. The contrast volume is a modifiable risk factor for development of CIN and previous studies established the association between contrast volume and the risk of CIN development^[@r33]-[@r35]^. In their study, Nikolsky et al.^[@r36]^ showed that increase of every 100 ml in the amount of contrast material resulted in a 30% increase in the odds ratio of CIN development. In the present study, the mean volume of contrast material was 182.6±58.6 mL which was comparable between groups. Anemia might be associated with CIN development. A different study published by Nikolsky et al. showed that decreased level of pre-procedural hematocrit is related to CIN development^[@r37]^.

In the present study, the mean hematocrit and hemoglobin levels were found to be lower in the CIN (+) group. Although hemoglobin was a predictor of CIN development in the univariate analysis, it lost its significance in the multivariate analysis. Heart failure has been reported to be a risk factor for CIN development in patients pwho underwent PCI^[@r38]^. Similarly, in this study the mean level of LVEF was signifincantly lower in the CIN group. Moreover, LVEF was an independent predictor of CIN development.

Conclusions
===========

In this study, we have determined that the prevelance of CIN development is significantly higher in patients diagnosed with non-STEMI and underwent PCI. In addition, GNRI is an independent predictor of CIN development and is better than BMI and serum albumin level in patients diagnosed with non-STEMI who underwent PCI.

Study limitations
-----------------

The main limitation of our study is its retrospective single- centered design. All patients diagnosed as post-PCI nephropathy which might be related to an extraneous causes as pre-renal disorders or cholestrol emboli. However, due to the nature of the study design it is not possible to diagnose these infrequently seen etiologies. Another limitation is that although we included all consecutive patients, some patients might be discharged after PCI without controlling their creatinine levels. But due to the sufficient number of patients in two groups, we believe that our results accurately reflect the patient population as a sample group. Another important limitation of study was that we included only patients diagnosed with non-STEMI.
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